ClinicalTrials.gg
RecruitingNCT05224778ASPIRE-DM1Updated Nov 3, 2026

DMCRN-02-001: Assessing Pediatric Endpoints in DM1

An observational study in Congenital Myotonic Dystrophy and CDM, sponsored by Virginia Commonwealth University. Recruiting at 5 sites in 2 countries. Open to participants aged Up to 59 Months. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Virginia Commonwealth University · Observational

How we know

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 2 months later.
Updated Nov 3, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
Up to 59 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies in Myotonic Dystrophy with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Myotonic Dystrophy · United States.

Planned enrollment
20th of 21
50 · median 125
Started
2022
with 5 others
Observational
21 of 43
15 open now
Primary completion
2026-12
later than 1 of 26 live
Registered
21st of 43
by date
Lead sponsor
6 of 43
Virginia Commonwealth University

Among the 43 studies in Myotonic Dystrophy with a site in United States, this one is the 20th largest by planned enrollment of the 21 observational ones that give a count, is one of 6 that started in 2022, is one of 21 observational ones, reaches primary completion later than 1 of the 26 other live ones, and was the 21st registered.

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

23 of the 43 studies in Myotonic Dystrophy with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: Up to 59 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Myotonic Dystrophy with a site in United States, or all of them as a file.
02

Study summary

The overall goal of the study is to establish valid clinical endpoint assessments for children with congenital myotonic dystrophy type 1 and develop biomarkers for the condition.

Read the detailed description

Myotonic dystrophy type-1 (DM1) is an autosomal dominant disorder caused by a toxic CTG repeat expansion in the 3'UTR of the DMPK gene. DM1 is the most common adult-onset muscular dystrophy, with an overall prevalence of 1:8000. In approximately 10-20% of individuals with DM1, the onset of symptoms occurs at birth, which is known as congenital myotonic dystrophy (CDM).

Previous studies have enrolled a very limited number of children with CDM.

The rationale for this study is to include a larger population of patients with CDM in order to determine developmental milestones, measures of physical and cognitive function and quality of life, and correlate functional outcome measures with potential biomarkers in CDM .

03

Conditions studied

  • Congenital Myotonic Dystrophy
  • CDM

Browse trials for

Keywords

  • Clinical Research
  • Myotonic dystrophy
  • Congenital Myotonic Dystrophy
  • CDM
04

Who can participate

Ages eligible
Up to 59 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

30 children with CDM

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age neonate to 3 years 11 months at enrollment.
  • A diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (\<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500).
  • Guardian is willing and able to sign consent and follow study procedures

Exclusion criteria

Exclusion Criteria:

  • Any other non-DM1 illness that would interfere with the ability or results of the study in the opinion of the site investigator
  • Significant trauma within one month
  • Internal metal or devices (exclusion for DEXA component)
  • History of bleeding disorder or count \<50,000
  • History of reaction to local anesthetic
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Congenital Myotonic Dystrophy (CDM)

    CDM group includes those aged neonate to 3 years, 11 months at enrollment. Individuals must have a diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (\<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4\>1,500).

06

What researchers measure

Primary outcomes

  1. To evaluate motor milestone attainment in individuals with CDM and ChDM and compare to typically developing children

    Milestone Assessment using Peabody definitions: This survey would ask parents to assess the age of motor milestones in days, months of infant age. Birth history, including prematurity, ventilatory status, and feeding problems would also be collected on the CRF. Feeding and ventilatory support, as well as height and weight will be collected at each study visit.

    Time frame: Through study completion at 18 months

Secondary outcomes

  1. Dysarthria Assessment

    A blinded, standardized video assessment tabulating language milestones by a trained rater will be conducted at each visit.

    Time frame: Through study completion at 18 months

  2. Vineland

    The Vineland will be administered by an interviewer to ensure standardized intake of data. This assessment will capture the adaptive function, including gross motor and fine motor, as reported by the parent proxy.

    Time frame: Through study completion at 18 months

  3. CCMDHI

    The congenital and childhood myotonic dystrophy health index is a disease specific patient or proxy reported outcome measure specific to these conditions. The current study will utilize the proxy version.

    Time frame: Through study completion at 18 months

  4. Domain Delta

    This assessment asks parents for global impression of change related to the baseline visit and will be used as an anchoring measure for the statistical analyses.

    Time frame: Through study completion at 18 months

  5. Gross Motor Function Measure (GMFM-88)

    The GMFM assesses functional abilities like lying/rolling, sitting, crawling/kneeling, standing, and walking, running, and jumping.

    Time frame: Through study completion 18 months

Other outcomes

  1. Correlate the functional outcome measures with potential biomarkers in CDM.

    Fine needle muscle biopsy:On the baseline visit, a fine needle aspirate will be performed. Biopsy will only be peformed once to minimize the risk. The procedure will be performed with local anesthesia (1% lidocaine without epinephrine and free of preservatives) of the vastus lateralis. Following lidocaine injection, a fine needle will be used to aspirate the quadriceps muscle to obtain a total of one aspirate. The aspirate will be flash frozen in liquid nitrogen. A similar procedure has been performed on adults with DM1, and the average biopsy yields sufficient tissue for RNA-Seq analysis.

    Time frame: Baseline

  2. Blood Sampling

    DNA and RNA samples will be processed by Virginia Commonwealth University.

    Time frame: Baseline, month 12, month 18

  3. Muscle mass, DEXA

    Lean muscle mass will be evaluated using serial DEXA scans as an exploratory endpoint. All sites will use a Hologic DEXA scanner. Investigators will evaluate whole body lean mass, left and right arm lean mass, and left and right leg lean mass. Particularly early in childhood, investigators would expect rapid changes in lean muscle mass. If there were a divergence between controls and subjects with CDM, this would provide evidence that CDM is a disorder of muscle maturity, as well as provide a potential biomarker.

    Time frame: Baseline, month 12, month 18

  4. World Health Organization (WHO) Motor Milestones

    The WHO Motor Milestones is a set of 6 standardized motor milestones that include 1) Sitting without support, 2) Standing with assistance, 3) Hands-\&-knees crawling, 4) Walking with assistance, 5) Standing alone, and 6) Walking alone.

    Time frame: Through study completion at 18 months

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Dec 2026, 52 months after the start.

Of 36 observational studies under Myotonic Dystrophy, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35. This study's planned 52 months is below that.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2022
First posted
Feb 4, 2022
StartActual
Aug 24, 2022
Primary completionEst.
Dec 2026was Oct 2026
CompletionEst.
Dec 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Dec 2026
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Primary completion Oct 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05224778
Responsible party
Sponsor
First posted
Feb 4, 2022
Start date
Aug 24, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 3, 2026

Study contacts

Ruby Langeslay
Contact
ruby.langeslay@vcuhealth.org
804-828-8481
Jennifer Raymond
Contact
jennifer.raymond@vcuhealth.org
804-828-6318
Nicholas E. Johnson, MD
principal investigator · Virginia Commonwealth University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion